The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers
Open Access
Abstract
The peremptory need to circumvent challenges associated with poorly differentiated epithelial endometrial cancers (PDEECs), also known as Type II endometrial cancers (ECs), has prompted therapeutic interrogation of the prototypically intractable and most prevalent gynecological malignancy. PDEECs account for most endometrial cancer-related mortalities due to their aggressive nature, late-stage detection, and poor response to standard therapies. PDEECs are characterized by heterogeneous histopathological features and distinct molecular profiles, and they pose significant clinical challenges due to their propensity for rapid progression. Regardless of the complexities around PDEECs, they are still being administered inefficiently in the same manner as clinically indolent and readily curable type-I ECs. Currently, there are no targeted therapies for the treatment of PDEECs. The realization of the need for new treatment options has transformed our understanding of PDEECs by enabling more precise classification based on genomic profiling. The transition from a histopathological to a molecular classification has provided critical insights into the underlying genetic and epigenetic alterations in these malignancies. This review explores the genomic landscape of PDEECs, with a focus on identifying key molecular subtypes and associated genetic mutations that are prevalent in aggressive variants. Here, we discuss how molecular classification correlates with clinical outcomes and can refine diagnostic accuracy, predict patient prognosis, and inform therapeutic strategies. Deciphering the molecular underpinnings of PDEECs has led to advances in precision oncology and protracted therapeutic remissions for patients with these untamable malignancies.Keywords
Funding Information
- Division of Research Capacity Development under the South African Medical Research Council Clinician Researcher Program (SAMRC-CRP) (57029, 23108, 138139)
- South African Medical Research Council (SAMRC) (57029, 23108, 138139)
- National Research Foundation (NRF) (57029, 23108, 138139)
This publication has 269 references indexed in Scilit:
- PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD‐1 blockadeClinical and Translational Medicine, 2024
- Characterization of mismatch‐repair/microsatellite instability‐discordant endometrial cancersCancer, 2023
- Molecular classification in endometrial cancer: Opportunities for precision oncology in a changing landscapeCancer, 2022
- High‐risk endometrial cancer proteomic profiling reveals that FBXW7 mutation alters L1CAM and TGM2 protein levelsCancer, 2021
- Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysisCancer, 2021
- PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancerCochrane Database of Systematic Reviews, 2019
- Laparoscopy versus laparotomy for the management of early stage endometrial cancerCochrane Database of Systematic Reviews, 2018
- Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancerCancer, 2017
- Mutations in POLE and survival of colorectal cancer patients – link to disease stage and treatmentCancer Medicine, 2014
- Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group studyCancer, 1987